Prognia
Drug Database
🇪🇺EU · EMAOpinion under re-examinationATC: N07XXOrphan Medicine

Daybu(trofinetide)

Rett Syndrome

Marketing Authorisation Holder: Acadia Pharmaceuticals B.V.

INN: trofinetide

Indication

Treatment of Rett syndrome in adults and paediatric patients 2 years of age and older

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Daybu — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.